fbpx

Actavis to acquire Allergan

Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan.

Actavis will pay $129.22 US in cash plus Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share.

The transaction has been unanimously approved by the boards of directors of both companies and is supported by the two management teams. This consequently puts an end to Valeant’s attempt to take over Allergan that began several months ago and about which much has been written.

The two companies combined will create one of the top 10 global growth pharmaceuticals with expected revenue of $23 billion in 2015. This deal should close in the second quarter of 2015.

For further details on the transaction: http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=883356

Featured Posts

EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read More
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read More
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read More
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read More
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more